Heart attack patients: which blood thinner is safer?

NCT ID NCT05183178

Completed Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study looked at over 17,000 people who had a heart attack to compare two blood thinners: prasugrel and ticagrelor. Hospitals switched from ticagrelor to prasugrel in a stepwise way to see which drug better prevents death, another heart attack, or stroke. The goal is to find the most effective treatment with fewer side effects like bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prasugrel and ticagrelor (blood thinners)
What this could lead to: If prasugrel proves better, it could become the preferred blood thinner for heart attack patients, reducing deaths and strokes.
What could go wrong: This is a completed Phase 4 study, but results may not apply to all patients, and both drugs carry bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME

Contacts and locations

Locations

Dep. Cardiology, Skånes universitetssjukhus

Lund, 22185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.